Adaptimmune Therapeutics
ADAP
ADAP was delisted on the 27th of October, 2025.
81 hedge funds and large institutions have $144M invested in Adaptimmune Therapeutics in 2024 Q3 according to their latest regulatory filings, with 17 funds opening new positions, 22 increasing their positions, 15 reducing their positions, and 12 closing their positions.
1,683% more call options, than puts
Call options by funds: $107K | Put options by funds: $6K
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
47% more repeat investments, than reductions
Existing positions increased: 22 | Existing positions reduced: 15
42% more first-time investments, than exits
New positions opened: 17 | Existing positions closed: 12
7% more funds holding
Funds holding: 76 → 81 (+5)
0.15% less ownership
Funds ownership: 10.04% → 9.89% (-0.15%)
4% less capital invested
Capital invested by funds: $150M → $144M (-$5.89M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Baillie Gifford & Co
Edinburgh,
United Kingdom
|
+$1.85M |
| 2 |
Morgan Stanley
New York
|
+$1.43M |
| 3 |
LFCM
Long Focus Capital Management
San Juan,
Puerto Rico
|
+$1.08M |
| 4 |
Marshall Wace
London,
United Kingdom
|
+$429K |
| 5 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$113K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BBA
Baker Bros. Advisors
New York
|
-$2.28M |
| 2 |
TCM
Tang Capital Management
San Diego,
California
|
-$1.7M |
| 3 |
MCMC
Matrix Capital Management Company
Portsmouth,
New Hampshire
|
-$1.47M |
| 4 |
PHS
PFM Health Sciences
San Francisco,
California
|
-$589K |
| 5 |
AI
Acuitas Investments
Seattle,
Washington
|
-$528K |
ADAP Hedge Fund Activity: Q3 2024 in Review
81 of the 6,965 institutional investors tracked by Wall St. Rank reported a position in Adaptimmune Therapeutics (ADAP) for Q3 2024, worth a combined $144M — down 3.9% from $150M a quarter earlier.
Buyers outnumbered sellers: 17 funds opened new ADAP positions and 12 closed out — a net gain of 5 holders — while 22 added to existing stakes and 15 trimmed.
The largest buyer was Baillie Gifford & Co, adding an estimated $1.85M. The largest seller was Baker Bros. Advisors, exiting entirely with an estimated $2.28M sold.
- 81 institutional investors held Adaptimmune Therapeutics (ADAP) as of Q3 2024, up from 76 in Q2 2024.
- Funds reported $144M of Adaptimmune Therapeutics stock for Q3 2024, down 3.9% quarter-over-quarter.
- 17 funds opened new Adaptimmune Therapeutics positions in Q3 2024 and 12 closed out, a net change of +5 holders.
- The largest Adaptimmune Therapeutics buyer in Q3 2024 was Baillie Gifford & Co, an estimated $1.85M added.
- The largest Adaptimmune Therapeutics seller in Q3 2024 was Baker Bros. Advisors, an estimated $2.28M sold.
Based on aggregated 13F filings for Q3 2024.